AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
January 22, 2025 08:30 ET
|
AIM ImmunoTech Inc.
Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS The early-onset broad-spectrum antiviral effect of...
Most Americans Support Pandemic Policies but Have Concerns About Implementation
January 14, 2025 09:53 ET
|
de Beaumont Foundation
Bethesda, Maryland, Jan. 14, 2025 (GLOBE NEWSWIRE) -- As the U.S. faces continuing infectious disease outbreaks, a new study shows that a majority of Americans are likely to support mitigation...
BioNTech gibt auf der 43. J.P. Morgan Healthcare-Konferenz Updates zur Geschäfts- und Pipeline-Entwicklung
January 14, 2025 06:45 ET
|
BioNTech SE
BioNTech fokussiert sich in der Umsetzung der Onkologie-Strategie auf tumorübergreifende (Pan-Tumor-) Therapieansätze basierend auf Kombinationen mit BNT327/PM8002 sowie den...
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
January 14, 2025 06:45 ET
|
BioNTech SE
Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a...
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
December 12, 2024 09:00 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has...
COVID Non-pharmaceutical Interventions Were Harmful Authoritarian Overreach, according to Journal of American Physicians and Surgeons
December 10, 2024 10:02 ET
|
Association of American Physicians and Surgeons
Pandemic control measures for COVID likely did more damage than the disease itself. They were imposed without sound evidence, ignoring social consequences.
tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients
December 09, 2024 04:00 ET
|
AKAMPION
- Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy Kiel, Germany, December 9, 2024 – tiakis Biotech AG, a clinical-stage biopharmaceutical company developing...
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
December 06, 2024 09:15 ET
|
AIM ImmunoTech Inc.
Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE...
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
November 15, 2024 07:51 ET
|
InflaRx N.V.
JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced...
BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe
October 28, 2024 08:05 ET
|
BlueWillow Biologics
ANN ARBOR, Mich., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BlueWillow Biologics, Inc., a clinical-stage biotech company pioneering the future of intranasal vaccines, today announced that the company will...